5 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital

Page 5 of 5

1. PMV Pharmaceuticals, Inc. (NASDAQ: PMVP)

Simons’ Stake Value: $137,461,000
Percentage of Jim Simons’ 13F Portfolio: 45.99%
Number of Hedge Fund Holders: 21

PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) is a pharmaceutical company that develops and discovers small molecule drugs to treat cancer and contagious disease. It was founded in 2013 and ranks first on the list of 10 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. PMV currently has a $1.56 billion market capitalization. 

On June 23, Cowen analyst Yaron Werber initiated a coverage on PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) with an “Outperform” rating. On May 14, the company declared that its first quarter of 2021 ended with $348.4 million in cash and marketable securities compared to $361.4 million a quarter earlier. 

Euclidean Capital owns 4.18 million shares in PMV Pharmaceuticals, Inc. (NASDAQ: PMVP), worth over $137 million, representing 45.99% of their portfolio. Samuel Isaly’s OrbiMed Advisors is the biggest stakeholder in the company, with 7.33 million shares worth over $241 million.

You can also take a peek at 10 Best Biotech Stocks To Invest In and Top 10 Sin Stocks To Buy.

Page 5 of 5